Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 9/20 | 0.44 |
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | MMP9 | P14780 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.39 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | TACR3 | P29371 | 1/20 | 0.38 |
| ▸ | NMBR | P28336 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4055562 | 0.92 | TACR1 (0.46) | TACR1MMP2MMP9KMT2AMEN1 | |
| SCHEMBL3953038 | 0.89 | TACR1 (0.41) | TACR1MMP2MMP9KMT2AMEN1 | |
| SCHEMBL13904515 | 0.89 | TACR1 (0.41) | TACR1MMP2MMP9KMT2AMEN1 | |
| SCHEMBL4145234 | 0.89 | TACR1 (0.42) | TACR1MMP2MMP9KMT2AMEN1 | |
| SCHEMBL4216399 | 0.87 | TACR1 (0.42) | TACR1MMP2MMP9KMT2AMEN1 | |
| SCHEMBL4058929 | 0.85 | TACR1 (0.50) | TACR1KMT2AMEN1CYP2D6TACR3 | |
| SCHEMBL4632722 | 0.84 | ITGB2 (0.41) | TACR1MMP2MMP9KMT2AMEN1 | |
| SCHEMBL14069910 | 0.83 | ITGB2 (0.43) | TACR1MMP2MMP9KMT2AMEN1 | |
| SCHEMBL4737824 | 0.83 | ITGB2 (0.43) | TACR1MMP2MMP9KMT2AMEN1 | |
| SCHEMBL4737837 | 0.83 | ITGB2 (0.43) | TACR1MMP2MMP9KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069328-A1 | ALPHA-ALKYL SUBSTITUTED N-ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2009-03-12 | — | — | US | claimed |
| WO-2009021980-A1 | α-ALKYL SUBSTITUTED N-ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-02-19 | — | — | WO | claimed |
| EP-2025669-A1 | Alpha-alkyl substituted N-acyltryptophanols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-02-18 | — | — | EP | claimed |
| US-20090069328-A1 | ALPHA-ALKYL SUBSTITUTED N-ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2009-03-12 | — | — | US | disclosed |
| WO-2009021980-A1 | α-ALKYL SUBSTITUTED N-ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-02-19 | — | — | WO | disclosed |
| EP-2025669-A1 | Alpha-alkyl substituted N-acyltryptophanols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069328-A1 | ALPHA-ALKYL SUBSTITUTED N-ACYLTRYPTOPHANOLS | FSHR, GNRHR, TPH1 | TACR1 167/4885MMP2 3861/4885MMP9 4077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.